Sugi Predict

Sugi Predict / Compounds / SCHEMBL718380

SCHEMBL718380

SCHEMBL718380

CC(C)(C)OC(=O)Nc1ccc(I)cc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 2/20 0.52
▸ PSMB8 P28062 1/20 0.50
▸ NAMPT P43490 1/20 0.50
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ MAP4K4 O95819 1/20 0.46
▸ PTPN11 Q06124 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TRPV1 Q8NER1 1/20 0.44
▸ MAPKAPK2 P49137 1/20 0.43
▸ DRD2 P14416 1/20 0.43
▸ PTGDR2 Q9Y5Y4 1/20 0.43
▸ LIPE Q05469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13055402 0.90 CYP17A1 (0.59) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL23619661 0.85 SMN1; SMN2 (0.62) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL20865536 0.85 CYP17A1 (0.68) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL178373 0.83 CYP17A1 (0.54) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL437131 0.83 CYP17A1 (0.54) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL730480 0.83 CYP17A1 (0.57) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL11925396 0.83 SMN1; SMN2 (0.66) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL977487 0.83 CYP17A1 (0.54) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL1455948 0.83 CYP17A1 (0.54) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL400342 0.82 CA1 (0.49) CYP17A1NAMPTCA1PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112939829-B Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2023-02-21 — — CN claimed
CN-112939829-A Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2021-06-11 — — CN claimed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 — — WO disclosed
EP-4741383-A1 COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG Tyligand Bioscience (Shanghai) Limited (CN) 2026-05-13 — — EP disclosed
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
WO-2025077773-A1 NOVEL TYPE I TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊维康医药有限责任公司 2025-04-17 — — WO disclosed
WO-2025011480-A1 COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG 泰励生物科技（上海）有限公司 2025-01-16 — — WO disclosed
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-12-26 — — US disclosed
US-12110278-B2 Selective JAK2 pseudokinase ligands and methods of use YALE UNIVERSITY (US) 2024-10-08 — — US disclosed
WO-2024153112-A1 PDE4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 瑞石生物医药有限公司 2024-07-25 — — WO disclosed
US-11932624-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-03-19 — — US disclosed
WO-1999043658-A1 HETEROCYCLIC SUBSTITUTED ANILINE CALCIUM CHANNEL BLOCKERS WARNER-LAMBERT COMPANY (US) 1999-09-02 — — WO disclosed
WO-1999007689-A1 ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS WARNER-LAMBERT COMPANY (US) 1999-02-18 — — WO disclosed
WO-1998050358-A1 INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY SMITHKLINE BEECHAM PLC (GB) 1998-11-12 — — WO disclosed
US-5726319-A Biphenyl substituted dipeptide analogs promote release of growth hormone MERCK & CO., INC. (US) 1998-03-10 — — US disclosed
US-5484786-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1996-01-16 — — US disclosed
US-5432194-A Antiallergens, antinflammatory agents ABBOTT LABORATORIES (US) 1995-07-11 — — US disclosed
US-5407959-A Antiallergens, antiinflammatory agents ABBOTT LABORATORIES (US) 1995-04-18 — — US disclosed
WO-1994026264-A1 (4-ALKOXYPYRAN-4-YL) SUBSTITUTED ARYLALKYLARYL-, ARYLALKENYLARYL-, AND ARYLALKYNYLARYLUREA INHIBITORS OF 5-LIPOXYGENASE ABBOTT LABORATORIES (US) 1994-11-24 — — WO disclosed
US-5346914-A Antiallergens, antiinflammatory agents ABBOTT LABORATORIES (US) 1994-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12110278-B2 Selective JAK2 pseudokinase ligands and methods of use JAK2, JAK1, MCL1 CYP17A1 1864/4885PSMB8 1726/4885NAMPT 4324/4885
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, USP2, MYCBP2 CYP17A1 3300/4885PSMB8 154/4885NAMPT 3324/4885
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 CYP17A1 2650/4885PSMB8 52/4885NAMPT 4861/4885
US-11932624-B2 MDM2 degraders and uses thereof MDM2, TP53, MDM4 CYP17A1 1067/4885PSMB8 335/4885NAMPT 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.